Canagliflozin and Metabolic Associated Fatty Liver Disease in Patients with Diabetes Mellitus: New Insights from CANVAS.

Angel N Borisov,Alexander Kutz,Emanuel R Christ,Markus H Heim,Fahim Ebrahimi

The Journal of clinical endocrinology and metabolism（2023）

引用 5|浏览4

暂无评分

摘要

In patients with T2DM, treatment with canagliflozin vs. placebo resulted in improvements in liver biochemistry, metabolism, and might beneficially affect liver fibrosis.

查看译文

关键词

SGLT-2 inhibitor, nonalcoholic fatty liver disease, metabolic associated fatty liver disease, diabetes, alanine aminotransferase, noninvasive tests of fibrosis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要